ABT vs MMC · P/E 25, rev $44.33B vs P/E 22, rev $24.46B
Abbott Laboratories (ABT) versus Marsh & McLennan Companies Inc (MMC) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported MMC revenue for 2024-12-31 was $24.46B. Net income was $4.12B. Revenue was up 7.6% from 2023-12-31 to 2024-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Not investment advice. Open the ABT and MMC stock pages for the full models.
Not investment advice.